{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:55:38Z","timestamp":1790916938609,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lenvatinib has been proven as a first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Traditional Chinese Medicine (TCM), particularly formulations targeting spleen strengthening and dampness elimination, has the potential for synergistic effects with targeted therapies. Researchers conducted a study to investigate the feasibility of combining spleen-strengthening and dampness-eliminating TCM granules with lenvatinib to improve survival rates in patients with unresectable HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a single-center retrospective cohort study that examined electronic medical records from one of the Beijing Royal Integrative Medicine Hospital between January 2023 and December 2025. Patients with unresectable HCC who received lenvatinib treatment as first-line therapy were divided into a combination group (TCM granules combined with lenvatinib,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009186) and a control group (lenvatinib alone,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009192). Balancing of baseline characteristics was done by use of propensity score matching (PSM). Overall survival (OS) was the primary endpoint; secondary endpoints included the incidence of adverse events, treatment duration, and the improvement of TCM syndromes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following 1:1 PSM, 156 patients were enrolled in each group. The combination group had a significantly longer median OS compared with the control group (18.7 months vs. 14.2 months; HR\u2009=\u20090.68, 95% CI: 0.52\u20130.89,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005). The incidence of Grade 3\u20134 adverse events was significantly lower in the combination group than in the control group (28.2% vs. 41.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018). Treatment duration was significantly prolonged in the combination group (9.8 vs. 7.2 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012), and the combination group also showed better improvements in TCM syndrome scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjunctive therapy with spleen-strengthening and dampness-eliminating TCM granules was associated with better survival outcomes and fewer adverse events in patients with unresectable HCC receiving lenvatinib. These findings provide a rationale for prospective trials evaluating the integration of TCM into modern oncological treatment paradigms for HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1946173","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:37:07Z","timestamp":1790915827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records"],"prefix":"10.3389","volume":"13","author":[{"given":"Canchao","family":"Sun","sequence":"first","affiliation":[{"name":"Tumor Center, Beijing Royal Integrative Medicine Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[{"name":"Tumor Center, Beijing Royal Integrative Medicine Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiye","family":"Sun","sequence":"additional","affiliation":[{"name":"Tumor Center, Beijing Royal Integrative Medicine Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000537947","article-title":"Characterization of tumor responses in patients with unresectable hepatocellular carcinoma treated with lenvatinib in the phase 3 randomized trial: REFLECT","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00348-w","article-title":"Safety and effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma in real-world clinical practice: an observational post-marketing study in Japan","author":"Furuse","year":"","journal-title":"Drugs \u2013 Real World Outcomes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14796694.2024.2397328","article-title":"Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study","volume":"56","author":"Kang","year":"2024","journal-title":"Cancer Res. Treat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/cancers15030876","article-title":"Important clinical factors affecting outcomes of lenvatinib therapy for unresectable hepatocellular carcinoma: an updated real-world multicenter analysis","volume":"15","author":"Kinslow","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","article-title":"The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J Liver Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3390\/cancers16183150","article-title":"Adverse events in targeted therapy for unresectable hepatocellular carcinoma predict clinical outcomes","volume":"16","author":"Imai","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12943-024-02136-2","article-title":"Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1374988","DOI":"10.3389\/fphar.2024.1374988","article-title":"Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma","volume":"15","author":"Lin","year":"2024","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2016.05.055","article-title":"The combination effects of shen-ling-bai-zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy","volume":"190","author":"Xi","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.19540\/j.cnki.cjcmm.20220421.201","article-title":"Research progress of shenling baizhu san and predictive analysis on its quality markers","volume":"47","author":"Lu","year":"2022","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/molecules29112545","article-title":"Integrating network pharmacology and experimental validation to decipher the mechanism of action of astragalus-atractylodes herb pair in treating hepatocellular carcinoma","volume":"29","author":"N\u00fa\u00f1ez-G\u00f3mez","year":"2024","journal-title":"Molecules"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3428253","DOI":"10.1155\/2017\/3428253","article-title":"Add-on therapy with traditional Chinese medicine improves outcomes and reduces adverse events in hepatocellular carcinoma: a meta-analysis of randomized controlled trials","volume":"2017","author":"Yang","year":"2017","journal-title":"Evid Based Complement Alternat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3390\/cancers15174271","article-title":"Predictive biomarkers for hepatocellular carcinoma immunotherapy","volume":"15","author":"Llueca","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1343755","DOI":"10.3389\/fphar.2024.1343755","article-title":"Shenling baizhu san ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"727154","DOI":"10.3389\/fphar.2021.727154","article-title":"A review of the ethnopharmacology, phytochemistry, pharmacology, application, quality control, processing, toxicology, and pharmacokinetics of the dried rhizome of atractylodes macrocephala","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"155494","DOI":"10.1016\/j.phymed.2023.155225","article-title":"Stigmasterol: remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma","volume":"128","author":"Huo","year":"2024","journal-title":"Phytomedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/CMAR.S242329","article-title":"The anti-cancer mechanisms of berberine: a review","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12943-025-02378-8","article-title":"The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine","volume":"24","author":"Su","year":"2025","journal-title":"Mol Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s41065-025-00456-x","article-title":"The bibliometric analysis of research on traditional Chinese medicine regulating gut microbiota for cancer treatment from 2014 to 2024","author":"Lei","year":"2025","journal-title":"Hereditas"},{"key":"B27","doi-asserted-by":"publisher","first-page":"115145","DOI":"10.1016\/j.jep.2022.115145","article-title":"Shenling baizhu san ameliorates ulcerative colitis by regulating the gut microbiota and its tryptophan metabolites: a complementary medicine to mesalamine","volume":"291","author":"Jiao","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00432-022-04082-2","article-title":"The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study","volume":"149","author":"Chen","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1528671","DOI":"10.3389\/fphar.2025.1528671","article-title":"Research advances in traditional Chinese medicine formulae and active components targeting lipid metabolism for hepatocellular carcinoma therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1002\/cam4.5661","article-title":"Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: a real-world cohort study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100591","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in nonviral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini","year":"2022","journal-title":"ESMO Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1946173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:37:18Z","timestamp":1790915838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1946173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1946173"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1946173","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1946173"}}